Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$107.19 USD
+0.19 (0.18%)
Updated May 3, 2024 04:00 PM ET
After-Market: $107.13 -0.06 (-0.06%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 41 - 60 ( 499 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Ayvakits Strong 3Q23 Powered by ISM, With Key HARBOR Data During ASH 23; Reit Buy and $85 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Solid Tumors - Week Ended October 13.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Late Breaking Abstract Round Up for ESMO 2023
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
ESMO 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Biotechnology- EORTC-NCI-AACR 2023 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Solid Tumors - Week Ended September 22.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Solid Tumors - Week Ended July 28.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Optimistic on Ayvakits Future Growth in ISM, Despite Investor Hesitation; Reit. Buy and $85 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department